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The first recombinant plant-derivedpharmaceutical protein (PDP) washuman serum albumin, initially pro-
duced in 1990 in transgenic tobacco and
potato plants (Sijmons et al, 1990). Fifteen
years on, the first technical proteins pro-
duced in transgenic plants are on the 
market, and proof of concept has been
established for the production of many
therapeutic proteins, including antibodies,
blood products, cytokines, growth factors,
hormones, recombinant enzymes and
human and veterinary vaccines (Twyman
et al, 2005). Furthermore, several PDP
products for the treatment of human dis-
eases are approaching commercialization
(Table 1), including recombinant gastric
lipase for the treatment of cystic fibrosis,
and antibodies for the prevention of 
dental caries and the treatment of 
non-Hodgkin’s lymphoma (Ma et al,
2003). There are also several veterinary
vaccines in the pipeline; Dow
AgroSciences (Indianapolis, IN, USA)
announced recently their intention to 
produce plant-based vaccines for the 
animal health industry.
As molecular farming has come of age,
there have been technological develop-
ments on many levels, including trans-
formation methods, control of gene
expression, protein targeting and accu-
mulation, the use of different crops as pro-
duction platforms (Twyman et al, 2003),
and modifications to alter the structural
and functional properties of the product.
One of the most important driving factors
has been yield improvement, as product
yield has a significant impact on economic
feasibility. Strategies to improve the
recombinant protein yield in plants include
the development of novel promoters, the
improvement of protein stability and
accumulation through the use of signals
that target the protein to intracellular
compartments, and the improvement of
downstream processing technologies
(Menkhaus et al, 2004).
Attention is now shifting from basic
research towards commercial exploitation,
and molecular farming is reaching the
stage at which it could challenge estab-
lished production technologies that use
bacteria, yeast and cultured mammalian
cells. In this review, we highlight not only
recent progress in molecular farming and
its potential for commercial drug develop-
ment and production, but also the regula-
tory control, biosafety and political
impacts of the technology, and its related
intellectual property (IP) issues.
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Table 1 | Plant-derived pharmaceutical proteins that are closest to commercialization for the
treatment of human diseases
Product Class Indication Company/Organization Crop Status
Various single- Antibody Non-Hodgkin’s Large Scale Biology Corp Viral vectors Phase I
chain Fv anti- lymphoma in tobacco
body fragments
CaroRx Antibody Dental caries Planet Biotechnology Inc. Transgenic Phase II
tobacco
E. coli heat- Vaccine Diarrhoea Prodigene Inc. Transgenic Phase I
labile toxin maize 
Arntzen group Transgenic Phase I
(Tacket et al, 1998) potato
Gastric lipase Therapeutic Cystic fibrosis, Meristem Therapeutics Transgenic Phase II
enzyme pancreatitis maize
Hepatitis B Vaccine Hepatitis B Arntzen group Transgenic Phase I
virus surface (Richter et al, 2000) potato
antigen Thomas Jefferson University/ Transgenic Phase I
Polish Academy of Sciences lettuce
Human Dietary Vitamin B12 Cobento Biotech AS Transgenic Phase II
intrinsic factor deficiency Arabidopsis
Lactoferrin Dietary Gastrointestinal Meristem Therapeutics Transgenic Phase I
infections maize
Norwalk virus Vaccine Norwalk virus Arntzen group Transgenic Phase I
capsid protein infection (Tacket et al, 2000) potato
Rabies Vaccine Rabies Yusibov et al (2002) Viral vectors Phase I
glycoprotein in spinach
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Ever since plants were first consideredas a production system for recombi-nant pharmaceutical proteins, many
potential benefits have been claimed. But,
as the technology has matured, so too has
the appreciation of the real advantages
that plants provide. There is little doubt
that transgenic plants offer an unparalleled
potential for scalability. Growing plants in
the field provides opportunities for virtually
unlimited production, and even if the
growing sites were strictly isolated to
avoid mixing or cross-pollination with
other crops, there are still many areas in
the world where large-scale production
could take place. Even under contain-
ment, it would be possible to grow a 
large number of pharmaceutical plants;
immense greenhouse facilities are already
used routinely by the horticultural and
food industries. It has been estimated that
250 acres of greenhouse space would be
sufficient to grow enough transgenic potato
plants to meet South East Asia’s annual
demand for the hepatitis B virus vaccine
(C. Arntzen, personal communication).
This level of production is clearly not
necessary for all protein pharmaceuticals,
but there are many cases in which large
quantities are required. Monoclonal anti-
bodies (mAbs), the largest class of biolog-
ics now in development, are often needed
in substantial amounts. For example, two
licensed antibodies, palivizumab and
infliximab, are used systemically at doses
of 10–15 mg kg–1 body weight. Many mAbs
are also being developed as topical mucosal
treatments, in which the dosage require-
ments and the need for repeated applica-
tions are likely to be much greater due to
the washing effects of mucosal secretions.
For example, the Guy’s 13 mAb, which
prevents colonization of the oral cavity by
Streptococcus mutans, required a dose of
22.5 mg per course of treatment (Ma et al,
1998). If this were administered to the
child population of Europe alone, a pro-
duction capacity of more than 1,000 kg per
year would be required.
Other topical agents are likely to be
needed at similar levels. HIV protein
microbicides could be used to prevent
HIV transmission by topical vaginal or rec-
tal application. However, these reagents
have not yet been tested in humans
because existing manufacturing capacities
are not able to produce sufficient amounts
for clinical tests. Studies in rhesus
macaques suggest that regular doses of at
least 5 mg are required to provide vaginal
coverage (Shattock & Moore, 2003). Thus,
to treat one million women, it would be
necessary to produce approximately 260 kg
of the protein per year. Current recombi-
nant protein-manufacturing capabilities
would be stretched to the limit if they were
to produce any of these topical reagents.
Producing therapeutics for the devel-
oped world is important, but there is also a
moral imperative to provide medicines for
developing countries. We will probably
see an effective vaccine against HIV in the
next few years, but as soon as it is devel-
oped, the global demand will far exceed
our ability to produce the compound.
Beyond HIV, there are many other infec-
tious diseases that require attention.
Recombinant hepatitis B vaccine, for
instance—produced in genetically modi-
fied yeast at present—cannot be made in
sufficient quantities and at a low enough
cost to meet the demands of developing
countries. The scalability of production in
transgenic plants could offer one of the
few practical solutions to overcome these
commercial and moral dilemmas.
Regardless of the availability of a vac-cine or protein therapeutic, cost is amajor factor for developing countries.
In addition, it is likely that new vaccines
will become more complex in composi-
tion, have longer development times and
consequently will cost more when they
come to market. Although the cost of pro-
duction in plants will be low, this may not
be the most important economic factor.
‘Cost of goods’ has relatively little impact
on the market price of new pharmaceuti-
cals, as illustrated by the dramatic fall in
prices when drugs lose patent protection
and generics become available. Several
other factors influence the price of new
vaccines, including regulatory require-
ments for drug development and manufac-
ture—which have become more stringent
and costly in recent years—the high failure
rate of new drugs, and the protection of IP.
Production in transgenic plants could
offer a new model for vaccine develop-
ment. The initial production technology is
low-tech and inexpensive, which facili-
tates entry into a pharmaceutical develop-
ment programme with relatively low initial
investment costs. This could allow the par-
ticipation of a wider audience beyond 
the well-established multinational pharma-
ceutical companies. Hopefully, developing
countries would be involved, and the focus
would shift to specific regional diseases
that do not otherwise feature prominently
in current drug development.
Another fundamental advantage of
plants has always been the range and
diversity of recombinant molecules that
they can potentially produce. As higher
eukaryotes, plants are able to synthesize
small peptides, polypeptides and complex
multimeric proteins, many of which can-
not be made in microbial systems (Ma 
et al, 2003). This versatility is reflected in
the increasing number of recombinant
proteins that has been reported in the liter-
ature. For many molecules, such as anti-
bodies, the presence of plant chaperones
that are homologous to those in mam-
malian cells is an important factor, as
these chaperones control the efficiency of
protein assembly and the extent of protein
degradation. In addition, targeting recom-
binant proteins to the plant secretory path-
way ensures that N-glycosylation and
other post-translational modifications take
place. The overall benefits are not only in
the range of recombinant proteins that can
be made in plants, but also in the flexibili-
ty that is allowed in the engineering of
new pharmaceutical proteins, which can
be designed with plant expression in mind
(Chargelegue et al, 2005).
There has been much interest in the
oral delivery of vaccines using edible
transgenic plant material, but one major
hurdle is the need to ensure an appropri-
ate immune response. Despite the advan-
tages of oral delivery, only the live (Sabin)
polio vaccine is delivered by this route at
present, which reflects important gaps in
our knowledge of the mucosal immune
system. However, PDPs would undoubtedly
…molecular farming is reaching
the stage at which it could
challenge established
production technologies that
use bacteria, yeast and cultured
mammalian cells
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assist vaccine programmes in developing
countries by simplifying immunization
regimens and reducing the costs of 
vaccine production, purification, storage
and administration. Nevertheless, it is
important to recognize that edible vac-
cines will not be delivered as fresh pro-
duce, as often suggested. A regulated
product requires controlled delivery of
standardized doses, so some level of pro-
cessing of the edible plant material would
be required. This need not include complex
purification, but is more likely to involve
simple and inexpensive food processing
techniques that are readily available, such
as freeze drying.
Although the potential advantages ofplants for PDP production are nowbecoming clearer, concerns remain
about low product yield, modified glycan
structures and the impact of pharmaceuti-
cal plants on the environment. Thus, the
importance of continuing basic research
and improving the technology cannot be
over-emphasized in the rush to commer-
cialization, and this must be achieved in a
manner consistent with evolving health
and environmental regulatory frameworks.
One example of an emerging produc-
tion technology is multiple-transgene direct
DNA transfer, which simultaneously intro-
duces all the components required for 
the expression of complex recombinant
macromolecules into the plant genome.
Nicholson et al (2005) delivered into rice
plants four transgenes that represent the
components of a secretory antibody.
Approximately 20% of the resulting plants
carried all four genes. Even though they
were delivered on different plasmids, such
multiple transgenes are frequently inherited
in a linked fashion (Chen et al, 1998). This
is a major advantage over alternative gene-
transfer methods that involve the stepwise
introduction of individual components 
followed by successive rounds of crossing
to generate plants containing the fully
assembled molecule. Direct DNA transfer
also allows the introduction into plants of
minimal expression cassettes that contain
only the promoter, open reading frame 
and terminator sequences. As no vector
backbone sequences are transferred, this
substantially increases transgene stability
and expression levels by preventing the
integration of potentially recombinogenic
sequences (Fu et al, 2000; Loc et al, 2002;
Christou & Kohli, 2005).
The differential glycosylation of proteins
produced in in vitro systems or in non-native
species has also been a potential concern.
In the case of plant glycosylation, it is unlikely
that plant glycans will be immunogenic or
allergenic, but altered glycans might affect
the functionality of some recombinant glyco-
proteins. Strategies are being devised to
‘humanize’ the plant glycosylation machin-
ery by inhibiting glycosylation enzymes
(Strasser et al, 2004), complemented, if
necessary, with mammalian counterparts
(Bakker et al, 2001).
Another maturing technology is the
synthesis of PDPs in plastids. This confers
significant advantages, primarily because
of the large number of transgene copies in
homoplasmic transformants, which allows
the production of extremely high levels of
recombinant protein (Bock, 2001; Daniell,
2002). The use of plastids as a vaccine pro-
duction platform seemed promising when
a tetanus toxin fragment (TetC) was pro-
duced at 25% of total soluble cellular 
protein in tobacco chloroplasts (Tregoning
et al, 2003). However, there have also
been several cases in which there was 
little or no expression of a target pharma-
ceutical molecule in plastids. Codon opti-
mization can be an issue, as was shown in
the case of TetC, in which transgenes with
a high AT content were expressed at the
highest levels. Recombinant proteins are
also subject to proteolysis in plastids.
Birch-Machin et al (2004) expressed high
levels of rotavirus VP6 protein in the
chloroplasts of young tobacco leaves, but
they diminished rapidly as the leaves
matured. The choice of target antigen must
therefore reflect an understanding of the
microenvironment in the chloroplast and
its functionality, to ensure efficient and
stable protein accumulation without
adversely affecting chloroplast function.
Whilst transformation and trans-gene expression are importanttechnological goals, it is also
necessary to consider the wider impact of
pharmaceutical plants on human and envi-
ronmental health. Two safety issues are
often raised in this context: the possible
transgene escape through pollen or seed
dispersal, and the potential for recombi-
nant molecules to enter the food chain.
Transformation of the plastid genome is
one of several strategies that have been put
forward to minimize transgene flow
through pollen (Daniell, 2002), as the plas-
tid DNA is maternally inherited in most
crop plants (Fig 1). An alternative is the use
of male sterile plant lines, in which no
pollen is produced. Seed dispersal could
be prevented by making seed viability
dependent on an exogenous stimulus, such
as the application of a chemical inducer
(Daniell, 2002). 
To avoid inadvertent entry into the
food chain, the use of non-food crops
such as tobacco is one option, but it is not
prudent to exclude a priori major crop
plants as hosts, particularly if the target
molecule poses little or no risk to environ-
mental or human health, such as recombi-
nant antibodies. In cases where direct oral
administration of the pharmaceutical is
desirable, edible plants are clearly pre-
ferred. Additional safety measures that
can be taken include the use of contained
production facilities, such as greenhouses,
the development of phenotypic markers
for identity preservation—for example,
green or purple fruit colour in tomato as a
label for transgenic lines expressing phar-
maceuticals—and the use of inducible
expression systems that require the appli-
cation of a chemical inducer to switch on
transgene expression. Fluorescent marker
proteins such as GFP or DsRed could be
used not only as visual selection agents,
but also as traceable markers for macro-
scopic detection of transgene activity. In
this way, the expression of a linked trans-
gene could be monitored visually (Harper
et al, 1999), and transgene movement
could be traced without molecular tech-
niques in agronomic and ecological stud-
ies (Fig 2). Tethering the transgene to an
inducible promoter makes expression
dependent on an externally applied stim-
ulus such as ethanol vapour, a method
Another fundamental advantage
of plants has always been the
range and diversity of
recombinant molecules that 
they can potentially produce
…most regulatory processes do
not readily accommodate
pharmaceutical crops because
the current regulations have
been developed for food and
feed crops…
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that works efficiently on potato tubers
after harvest (Sweetman et al, 2002).
Control of expression is also an issue in
the case of plastid transgenes, particularly
in view of the high yields that can be
achieved. One promising approach is to
use a nuclear-expressed, plastid-targeted
phage T7 RNA polymerase to transcribe
the plastid transgene selectively (Magee 
et al, 2004).
The regulation of pharmaceuticalcrops is still a developing field, withthe majority of experience coming
from North America. In the USA, most
field trials for genetically modified organ-
isms (GMOs) rely on risk mitigation in the
form of strict confinement and regular
inspections to limit any environmental
exposure. These measures have become
stricter for pharmaceutical crops during
the past few years. Environmental assess-
ments are only required when a regulated
article is being petitioned for deregulated
status, such as before widespread environ-
mental release. Until then, field trials are
designed to confine the regulated article,
and in this way reduce the risk by limiting
exposure. There are no plans at present to
deregulate any pharmaceutical crops in
the USA, and as such they are likely to
remain under experimental permit for the
foreseeable future. 
In the EU, regulators strive to consider
pharmaceutical crops on a case-by-case
basis. However, most regulatory processes
do not readily accommodate pharmaceu-
tical crops because the current regulations
have been developed for food and feed
crops and their potential impact on the
environment. There have been limited
attempts so far to adapt these regulations
for pharmaceutical crops, but at present
there is no ‘natural home’ for assessing
pharmaceutical crops in the EU regulatory
process. A similar situation exists in South
Africa, where applications for the con-
tained release of a pharmaceutical crop
and subsequent field trial must follow the
same steps as an application for a normal
GMO, and should include the necessary
risk-assessment information.
Many of the plants being developed for
the production of PDPs are food and feed
crops. A first step in developing a regulatory
framework is to consider whether PDP
products and by-products can be ade-
quately segregated from other commodi-
ties, particularly those intended for human
and animal consumption. A case in 2002,
involving Prodigene Inc. (College Station,
TX, USA), showed that, although safe-
guards are in place to prevent adulterated
food products entering the food chain, the
biology of the production crop and subse-
quent rotation crops must be taken into
account in regulation and containment
strategies.
Most of the steps that prevent pharma-
ceutical crops becoming mixed with food
crops involve relatively low-tech mea-
sures, such as meticulous planning and
execution of each step in the production
process. The crop must be grown in isola-
tion from breeding materials to avoid
genetic and mechanical mixing. Field 
trials need to be carried out in isolation,
away from conventional agricultural crop
trials. Parent seed for commercial produc-
tion and the commercial crops themselves
must be isolated from other plants of the
same species or wild relatives, to avoid
stray pollination. In practice, such mixing
might be difficult to detect, so effective
handling and labelling protocols are also
essential, in addition to the use of
labelling technology, such as fluorescent
markers, as described earlier.
Many of these considerations are
equally relevant to existing conventional
crops where genetic admixtures can
occur, and successful co-existence strate-
gies are already in widespread practice.
One example is the production of ‘high-
erucic acid rape’ (HEAR), which yields
specialized oils for industrial processing.
Erucic acid is highly toxic, and HEAR
seeds can become mixed with seeds from
food and feed oilseed rape; therefore pro-
duction protocols are tightly defined and
controlled. In North America, producers
are required to grow HEAR under contract
registration, and the Canadian Food
Inspection Agency (CFIA) mandate this
requirement at the time of varietal regis-
tration (Smyth & Phillips, 2002). Similarly,
measures are taken to ensure that opium
poppy seeds used for food are completely
separated from the other plant parts from
which opiates are extracted. The produc-
tion of opium poppies is also carried out
Fig 1 | Reciprocal crosses showing maternal inheritance of a transgene integrated into the chloroplast
genome. Surface-sterilized seeds are germinated on antibiotic-containing medium and analysed for
inheritance of the chloroplast-encoded antibiotic resistance gene. Selfed plastid transformants
(‘transplastomics’) and crosses with a plastid transformant as the maternal parent gives rise to uniformly
resistant (green) progeny, whereas seeds collected from wild-type plants yield antibiotic-sensitive 
(white) seedlings. Most importantly, pollen from transplastomic plants does not transmit the transgene 
(cross-labelled in red), thus greatly reducing transgene escape.
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in complete physical isolation (Mascia &
Flavell, 2004).
As well as adhering to the same strict
regulations as conventional GM food and
feed crops, PDPs also need to satisfy the
regulations set out by the agencies that
oversee the production of pharmaceuticals.
Both the US Food and Drug Administration
(FDA) and the European Agency for the
Evaluation of Medicinal Products (EMEA)
published draft documents in 2002 that
addressed quality aspects in the processing
of medicinal products made from GM
plants (FDA 2002; EMEA 2002). These
guidelines address the potential scientific
and technological hurdles that must be
overcome before plants can be consid-
ered as a viable alternative for existing 
biopharmaceutical production systems
(Drossard, 2004).
One of the most important goals inmolecular farming is the develop-ment of new drugs and vaccines
targeting important diseases in both devel-
oped and developing countries. Here,
government and foundation funding of
PDP production represents a new genera-
tion of public-sector initiatives that seek to
rectify a widely acknowledged imbalance:
the lack of investment in research and
development focusing on health technolo-
gies for the poor (CMH, 2001). The private
sector cannot address this imbalance ade-
quately because it needs to make a return
on its investment, which the market for the
poor does not provide. The public sector is
therefore making substantially increased
investments in health technology innova-
tion through public–private partnerships.
These product-development partnerships
face a common problem: how to manage
IP. This is no small challenge. IP manage-
ment is a complex and empirical field that
embraces many issues including patent-
ing, the protection of confidential infor-
mation and the formation of cooperative
research and development programmes
(Mahoney, 2004). In an area such as mole-
cular farming, in which there are many
organizational actors, there are three over-
riding challenges to IP management:
determining freedom to operate, securing
new IP as it is developed, and deploying 
IP to enable product development in 
partnership with private companies.
For public-sector support of PDPs to
achieve its goals, it will be necessary to
carry out an in-depth freedom-to-operate
(FTO) assessment, which provides a clearer
picture of the patents that do, may, and do
not stand in the way of developing prod-
ucts. An FTO assessment provides a good
sense of the IP issues of concern for any
project and helps to minimize the
chances of running into costly problems.
A valuable adjunct to the FTO analysis
would be the creation of a computer 
database of all the relevant patents in
molecular farming.
Public-sector groups involved in PDP
production are often dedicated to achiev-
ing a social goal. To accomplish this, they
should use humanitarian licensing prac-
tices. For example, if a group helps to
develop a new therapeutic monoclonal
antibody, it could license the technology
to companies in Europe, but it could also
reserve the right to license companies in
developing countries that would make the
product available to the poor at prices
near the cost of production. Whereas most
scientists and their institutes will cheerfully
support these ideals, in practice most IP is
still not developed with humanitarian
licensing practices in mind, and efforts to
achieve this must be undertaken in a
proactive manner. One innovative approach
has been adopted by the Pharma–Planta
Consortium, an EU-funded project to
develop recombinant pharmaceuticals in
plants (www.pharma-planta.org), in which
76 scientists have signed a Statement 
of Intent for Humanitarian Use for all
knowledge that is generated during the
project.
IP management is a complex process,
but there are clear steps that public-sector
groups concerned with health can take to
achieve the goal of making safe and effec-
tive health products available to all. These
steps will help to improve the socio-political
status of molecular farming, a subject that is
discussed in the following section.
The media-led furore over GM foodin Europe illustrated very clearlythat although research and develop-
ment success and social acceptance are
both necessary for the success of new
biotechnology, social rejection alone is
sufficient to derail the endeavour. There is
frequently the perception—whether sci-
entifically justified or not—that the mix-
ing of pharmaceutical crops with food
and feed crops may be harmful to human
health, and hence there can be added
pressures from the farming, food and
retail industries. The regulatory systems in
most parts of the world deal principally
with scientific risk assessment and are not
usually set up to consider socio-political
questions. These need to be dealt with in a
broader societal context. The regulatory
system in South Africa, for instance, has a
provision stating that the Council may
consider the socio-economic impact of
the release on a community living in the





Fig 2 | Detection of transgenic seeds using red fluorescent protein (DsRed) as a visible marker. Maize
and tobacco seeds (A and B) observed under green light (C and D). Courtesy of T. Rademacher (RWTH,
Aachen, Germany).
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such as the Union of Concerned Scientists
have described PDP crops as biological
factories producing chemical products
that present important new policy chal-
lenges requiring public debate. Others,
including Friends of the Earth and
GeneWatch, have stated that the potential
for inadvertent consumption of a drug-
producing crop and the potential for gene
flow to other crops mean that food crops
should not be used. Food processors, such
as the Grocery Manufacturers of America
Inc., are nervous about the risk of mixing
food and pharmaceutical crops, and have
suggested that the US Department of
Agriculture “should adopt…a presump-
tion against the use of food or feed crops
for drug or industrial compound manufac-
turing” (GMA, 2003). They further recom-
mend that these types of non-food crop
should not be grown where crops are
commonly grown for food or feed.
However, as discussed earlier, the 
merits of using food crops should not be
ignored. In particular, dry seed crops, such
as maize, rice, wheat, barley, soybean and
pea, offer huge benefits in terms of scala-
bility as well as protein stability (Stoger 
et al, 2002). Seeds are natural storage
organs, with the optimal biochemical
environment for the accumulation of large
amounts of protein. In this form, proteins
can be transported from farm to produc-
tion factories without the loss of stability.
Downstream protein extraction from seeds
is also easier than from vegetable or leaf
tissue, which will inevitably reduce pro-
duction costs and benefit the consumer.
Food crops as production hosts should
therefore not be dismissed, particularly if
the target molecule poses little or no envi-
ronmental risk. Whatever the outcome of
the debates and regulation, it will be
essential to manage all of the related per-
ceptions, technical issues and risks on a
case-by-case basis.
As society learns more about transgenic
crops and how to control any potentially
harmful effects, the need for regulation
may decrease. Until that happens, regulations
reassure the public that the new technology
is not harmful to them or the environment.
PDPs offer a real opportunity for the pub-
lic to see a distinct, advantageous end use
for this technology, with the ability to pro-
duce therapeutic drugs more efficiently
and with less expense. This has not
escaped public attention: when activists
destroyed a transgenic maize crop, which
was being grown by the French biotech-
nology company Meristem Therapeutics to
produce recombinant gastric lipase for the
treatment of cystic fibrosis or pancreatitis,
the high-profile NGOs were quick to 
distance themselves and deny involve-
ment after the Cystic Fibrosis Patients
Organization defended the technology.
However, industry needs to learn from
past mistakes and should be seen to regu-
late the technology tightly to gain public
trust. Any mishandling is likely to foster
negative attitudes and could delay the
PDP agenda—the provision of inexpen-
sive drugs to all those who need them—by
many years.
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